Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System

Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users

(2021) Ariel Dora Stern et al.   HEALTH AFFAIRS

Characteristics of successful changes in health care organizations: an interview study with physicians, registered nurses and assistant nurses

(2020) Per Nilsen et al.   BMC HEALTH SERVICES RESEARCH

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

(2020) Liese Barbier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb

(2020) Shubha Bhat et al.   Journal of Managed Care & Specialty Pharmacy

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice

(2020) Liese Barbier et al.   BIODRUGS

Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center

(2020) Mara N Villanueva et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

(2019) Thomas Bo Jensen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The Clinical Implications of Nocebo Effects for Biosimilar Therapy

(2019) Luana Colloca et al.   Frontiers in Pharmacology

A novel approach to support implementation of biosimilars within a UK tertiary hospital

(2019) Katherine Saxby et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

(2018) Hillel P. Cohen et al.   DRUGS

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product

(2018) Kyoung Hoon Lee et al.   mAbs

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

(2018) Michinori Ogura et al.   Lancet Haematology

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

(2018) Emily Leonard et al.   Journal of Managed Care & Specialty Pharmacy

Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars

(2017) András Inotai et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

(2017) Won Seog Kim et al.   Lancet Haematology

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians

(2016) Hillel Cohen et al.   ADVANCES IN THERAPY

A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

(2016) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey

(2016) Aaron S. Kesselheim et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Patient attitudes and understanding about biosimilars: an international cross-sectional survey

(2016) Ira Jacobs et al.   Patient Preference and Adherence